Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 13.39
APRI's Cash to Debt is ranked higher than
83% of the 910 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. APRI: 13.39 )
APRI' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 13.39

Equity to Asset 0.61
APRI's Equity to Asset is ranked higher than
69% of the 823 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. APRI: 0.61 )
APRI' s 10-Year Equity to Asset Range
Min: -0.04   Max: 0.87
Current: 0.61

-0.04
0.87
Interest Coverage No Debt
APRI's Interest Coverage is ranked higher than
82% of the 550 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 104.14 vs. APRI: No Debt )
APRI' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: -16.11
M-Score: 8.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -122.76
APRI's Operating margin (%) is ranked higher than
50% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.67 vs. APRI: -122.76 )
APRI' s 10-Year Operating margin (%) Range
Min: -25298.53   Max: -86.86
Current: -122.76

-25298.53
-86.86
Net-margin (%) -75.75
APRI's Net-margin (%) is ranked higher than
51% of the 861 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. APRI: -75.75 )
APRI' s 10-Year Net-margin (%) Range
Min: -23786.76   Max: -83.71
Current: -75.75

-23786.76
-83.71
ROE (%) -52.50
APRI's ROE (%) is ranked higher than
52% of the 882 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. APRI: -52.50 )
APRI' s 10-Year ROE (%) Range
Min: -1512.53   Max: -38.69
Current: -52.5

-1512.53
-38.69
ROA (%) -26.39
APRI's ROA (%) is ranked higher than
53% of the 914 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. APRI: -26.39 )
APRI' s 10-Year ROA (%) Range
Min: -217.31   Max: -37.07
Current: -26.39

-217.31
-37.07
ROC (Joel Greenblatt) (%) -856.24
APRI's ROC (Joel Greenblatt) (%) is ranked higher than
50% of the 908 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.66 vs. APRI: -856.24 )
APRI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2232.26   Max: -68.6
Current: -856.24

-2232.26
-68.6
Revenue Growth (3Y)(%) -45.00
APRI's Revenue Growth (3Y)(%) is ranked higher than
50% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.60 vs. APRI: -45.00 )
APRI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 105.1
Current: -45

0
105.1
EBITDA Growth (3Y)(%) -17.50
APRI's EBITDA Growth (3Y)(%) is ranked higher than
57% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. APRI: -17.50 )
APRI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 49.9
Current: -17.5

0
49.9
EPS Growth (3Y)(%) -43.00
APRI's EPS Growth (3Y)(%) is ranked higher than
53% of the 675 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. APRI: -43.00 )
APRI' s 10-Year EPS Growth (3Y)(%) Range
Min: -44.3   Max: 78.2
Current: -43

-44.3
78.2
» APRI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with APRI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.10
APRI's P/B is ranked higher than
73% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.53 vs. APRI: 3.10 )
APRI' s 10-Year P/B Range
Min: 1.43   Max: 127.5
Current: 3.1

1.43
127.5
P/S 4.80
APRI's P/S is ranked higher than
68% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.89 vs. APRI: 4.80 )
APRI' s 10-Year P/S Range
Min: 0.78   Max: 1380
Current: 4.8

0.78
1380
EV-to-EBIT -2.80
APRI's EV-to-EBIT is ranked lower than
51% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.22 vs. APRI: -2.80 )
APRI' s 10-Year EV-to-EBIT Range
Min: -20.7   Max: -1.1
Current: -2.8

-20.7
-1.1
Current Ratio 2.88
APRI's Current Ratio is ranked higher than
75% of the 893 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.41 vs. APRI: 2.88 )
APRI' s 10-Year Current Ratio Range
Min: 0.12   Max: 85.68
Current: 2.88

0.12
85.68
Quick Ratio 2.83
APRI's Quick Ratio is ranked higher than
80% of the 892 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.81 vs. APRI: 2.83 )
APRI' s 10-Year Quick Ratio Range
Min: 0.12   Max: 85.68
Current: 2.83

0.12
85.68

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.32
APRI's Price/Net Cash is ranked higher than
96% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APRI: 4.32 )
APRI' s 10-Year Price/Net Cash Range
Min: 3.4   Max: 281.25
Current: 4.32

3.4
281.25
Price/Net Current Asset Value 3.96
APRI's Price/Net Current Asset Value is ranked higher than
95% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. APRI: 3.96 )
APRI' s 10-Year Price/Net Current Asset Value Range
Min: 3.4   Max: 281.25
Current: 3.96

3.4
281.25
Price/Tangible Book 3.06
APRI's Price/Tangible Book is ranked higher than
79% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.24 vs. APRI: 3.06 )
APRI' s 10-Year Price/Tangible Book Range
Min: 2.1   Max: 90.15
Current: 3.06

2.1
90.15
Price/Median PS Value 0.28
APRI's Price/Median PS Value is ranked higher than
98% of the 949 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.29 vs. APRI: 0.28 )
APRI' s 10-Year Price/Median PS Value Range
Min: 0.09   Max: 139.71
Current: 0.28

0.09
139.71
Earnings Yield (Greenblatt) -35.70
APRI's Earnings Yield (Greenblatt) is ranked lower than
53% of the 907 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. APRI: -35.70 )
APRI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -35.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:NXEN.Germany,
Apricus Biosciences, Inc., was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. Its products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory submission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with our NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.
» More Articles for APRI

Headlines

Articles On GuruFocus.com
CEO and CFO Buys Weekly Update May 29 2013 

More From Other Websites
Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline... Dec 22 2014
7:33 am Apricus Biosciences announces year-end 2014 update and 2015 plans to advance its clinical... Dec 22 2014
Apricus Biosciences Announces Year-End 2014 Update and 2015 Plans to Advance Its Clinical Pipeline... Dec 22 2014
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 15 2014
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer Dec 15 2014
Apricus Biosciences Appoints Barbara Troupin, M.D. as Chief Medical Officer Dec 15 2014
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in... Dec 04 2014
Apricus Biosciences Announces First Patient Enrolled in Phase 2a Clinical Trial for RayVa(TM) in... Dec 04 2014
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Change in Directors or Principal Officers Dec 02 2014
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer Dec 02 2014
Apricus Biosciences Appoints Brian T. Dorsey as Chief Development Officer Dec 02 2014
APRICUS BIOSCIENCES, INC. Financials Nov 18 2014
10-Q for Apricus Biosciences, Inc. Nov 12 2014
APRICUS BIOSCIENCES, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 10 2014
APRICUS BIOSCIENCES, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2014
Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 10 2014
Q3 2014 Apricus Biosciences Inc Earnings Release - Before Market Open Nov 10 2014
Apricus Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update Nov 10 2014
Apricus Biosciences to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday,... Nov 07 2014
Apricus Biosciences to Host Third Quarter 2014 Earnings Conference Call and Webcast Live on Monday,... Nov 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK